Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0023890 (
cirrhosis
)
42,195
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cancer testis (CT) antigens have received particular attention in cancer immunotherapy.
OY-TES-1
is a member of CT antigens. This study was to evaluate
OY-TES-1
expression and immunogenicity in hepatocelluar carcinoma (HCC).
OY-TES-1
mRNA expression was detected in 56 HCC tissues and 5 normal liver tissues by reverse transcriptase PCR (RT-PCR). Of the 56 cases of HCC tissues tested, 37 cases had tumor and matched adjacent non-cancer tissues and were subjected to both RT-PCR and quantitative real-time PCR.
OY-TES-1
protein was subsequently observed on a panel of tissue microarrays. Sera from patients were tested for
OY-TES-1
antibody by ELISA. To identify
OY-TES-1
capable of inducing cellular immune response,
OY-TES-1
protein was used to sensitize dentritic cells and the cytotoxicity effect was measured in vitro. The results showed that
OY-TES-1
mRNA was highly expressed in 41 of the 56 (73.21%) HCC tissues, whereas none in 5 normal liver tissues.
OY-TES-1
mRNA was frequently expressed not only in HCC tissues (72.97%, 27/37), but also in paired adjacent non-cancer tissues (64.86%, 24/37). But the mean expression level of
OY-TES-1
mRNA in HCC tissues was significantly higher than that in adjacent non-cancer tissues (0.76854 vs. 0.09834, P=0.021). Immunohistochemistry showed that
OY-TES-1
protein expression was detected in 6 of the 49 cases of HCC tissues, and absent in 9 cases of normal liver and 6 cases of
cirrhosis
tissues. Seropositivity was detected in 10 of the 45 HCC patients, but not detected in 17
cirrhosis
patients and 76 healthy donors. The specific cytotoxic T cells elicited by
OY-TES-1
could kill HLA-A
2
+
HCC cell line which expressed
OY-TES-1
. The target lysis was mainly HLA class I -dependent and could be blocked by antibodies against monomorphic HLA class I but not HLA class II molecule. In summary,
OY-TES-1
expression is up-regulated in HCC tissues and can be recognized by humoral and cellular responses, which suggests that
OY-TES-1
is an attractive target for tumor immunotherapy in HCC.
...
PMID:Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. 3286 83